plse20260607c_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): June 11, 2026
| Pulse Biosciences, Inc. | ||
| (Exact Name of Registrant as Specified in Its Charter) | ||
| Delaware | 001-37744 | 46-5696597 |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 3957 Point Eden Way | ||
| Hayward, California 94545 | ||
| (Address of Principal Executive Offices) (Zip Code) | ||
| 510-906-4600 | ||
| (Registrant’s Telephone Number, Including Area Code) | ||
| Not Applicable |
| (Former Name or Former Address, If Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered |
| Common stock, $0.001 par value per share | PLSE | The Nasdaq Stock Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.07 | SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS. |
On June 11, 2026, Pulse Biosciences, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The Annual Meeting was a virtual meeting held via live audio webcast. The stockholders of the Company voted on the following items at the Annual Meeting:
| 1. | to elect seven directors to hold office until the Company’s 2027 annual meeting and until their successors are duly elected and qualified, subject to earlier resignation or removal; |
| 2. | to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026; |
The voting results for each of these proposals are detailed below:
| 1. | Election of Directors |
| Nominee | For | Against | Abstained | Broker Non-votes | ||||
| Robert W. Duggan | 33,443,582 | 1,583,174 | 388 | 10,974,550 | ||||
| Paul A. LaViolette | 34,264,295 | 759,401 | 3,448 | 10,974,550 | ||||
| Maria Sainz | 35,007,101 | 18,349 | 1,694 | 10,974,550 | ||||
| Manmeet S. Soni | 33,560,875 | 1,464,574 | 1,695 | 10,974,550 | ||||
| Darrin R. Uecker | 34,246,413 | 779,036 | 1,695 | 10,974,550 | ||||
| Richard A. van den Broek | 34,278,978 | 746,471 | 1,695 | 10,974,550 | ||||
| Mahkam Zanganeh, D.D.S. | 34,241,938 | 783,511 | 1,695 | 10,974,550 |
Each director nominee was duly elected to serve until the 2027 Annual Meeting and until his or her successor is duly elected and qualified.
| 2. | Ratification of Appointment of Independent Registered Public Accounting Firm |
| For | Against | Abstained | Broker Non-votes | |||
| 45,976,355 | 8,265 | 17,074 | N/A |
The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| PULSE BIOSCIENCES, INC. | |||
| Date: June 11, 2026 | By: | /s/ Jon Skinner | |
| Jon Skinner | |||
| Chief Financial Officer (Principal Financial Officer) | |||